Biosynthetic And structural studies of a heavy chain disease protein

por Ein, Daniel, Buell, Donald N., Fahey, John L.
Publicado em 1969

SEPARATION OF HUMAN LYMPHOID CELLS INTO G(1), S, AND G(2) CELL CYCLE POPULATIONS BY USE OF A VELOCITY SEDIMENTATION TECHNIQUE

por Everson, Lloyd K., Buell, Donald N., Rogentine, G. Nicholas
Publicado em 1973

Insulin-Dependent Regulation of Insulin Receptor Concentrations: A Direct Demonstration in Cell Culture

por Gavin, James R., Roth, Jesse, Neville, David M., De Meyts, Pierre, Buell, Donald N.
Publicado em 1974

Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans

por Bekersky, Ihor, Fielding, Robert M., Dressler, Dawna E., Lee, Jean W., Buell, Donald N., Walsh, Thomas J.
Publicado em 2002

Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amp...

por Bekersky, Ihor, Fielding, Robert M., Dressler, Dawna E., Lee, Jean W., Buell, Donald N., Walsh, Thomas J.
Publicado em 2002

Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with Aspergillus Species and Other Filamentous Fungi: Maximum Tolerat...

por Walsh, Thomas J., Goodman, Jesse L., Pappas, Peter, Bekersky, Ihor, Buell, Donald N., Roden, Maureen, Barrett, John, Anaissie, Elias J.
Publicado em 2001

Population Pharmacokinetics of Micafungin in Neonates and Young Infants

por Hope, William W., Smith, P. Brian, Arrieta, Antonio, Buell, Donald N., Roy, Michael, Kaibara, Atsunori, Walsh, Thomas J., Cohen-Wolkowiez, Michael, Benjamin, Daniel K.
Publicado em 2010

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

por Andes, David, Ambrose, Paul G., Hammel, Jeffrey P., Van Wart, Scott A., Iyer, Varsha, Reynolds, Daniel K., Buell, Donald N., Kovanda, Laura L., Bhavnani, Sujata M.
Publicado em 2011

Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients

por Seibel, Nita L., Schwartz, Cindy, Arrieta, Antonio, Flynn, Patricia, Shad, Aziza, Albano, Edith, Keirns, James, Lau, Wendi M., Facklam, David P., Buell, Donald N., Walsh, Thomas J.
Publicado em 2005

Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates

por Smith, P Brian, Walsh, Thomas J, Hope, William, Arrieta, Antonio, Takada, Akitsugu, Kovanda, Laura L, Kearns, Gregory L, Kaufman, David, Sawamoto, T, Buell, Donald N, Benjamin, Daniel K
Publicado em 2009

Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing

por Hope, William W., Seibel, Nita L., Schwartz, Cindy L., Arrieta, Antonio, Flynn, Patricia, Shad, Aziza, Albano, Edythe, Keirns, James J., Buell, Donald N., Gumbo, Tawanda, Drusano, George L., Walsh, Thomas J.
Publicado em 2007

Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants

por Benjamin, Daniel K, Smith, P Brian, Arrieta, Antonio, Castro, Lisa, Sánchez, Pablo J, Kaufman, David, Arnold, Leah J, Kovanda, Laura L, Sawamoto, Taiji, Buell, Donald N, Hope, William W, Walsh, Thomas J
Publicado em 2009

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis()

por Denning, David W., Marr, Kieren A., Lau, Wendi M., Facklam, David P., Ratanatharathorn, Voravit, Becker, Cornelia, Ullmann, Andrew J., Seibel, Nita L., Flynn, Patricia M., van Burik, Jo-Anne H., Buell, Donald N., Patterson, Thomas F.
Publicado no J Infect (2006)